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1. Introduction
Uveitis is one of the leading causes of blindness in the world. It is estimated that uveitis
accounts for 10%-15% of the blindness in the western world [1]. More importantly, the
blindness caused by uveitis is mostly permanent and irreversible since the retina and optic
nerve are damaged by inflammation.
Uveitis was previously defined as inflammation of the uveal tract, which is classically
composed of the iris, ciliary body and choroid. Yet in common practice, uveitis refers to
inflammation involving any intraocular structure and therefore carries the following names:
iritis, iridocyclitis, parsplanitis, posterior uveitis, choroiditis, retinitis and retinal vasculitis. It
is usually classified into infectious and noninfectious origins on the basis of predominant
etiological characteristics. Behcet’s disease (BD) is thought to be an autoinflammatory disease,
while Vogt-Koyanagi-Harada (VKH) syndrome is an autoimmune disease. Therefore, we
chose BD and VKH, which are two important representative entities among the noninfectious
uveitis class, to discuss the recent advances in our knowledge on the pathogenesis of uveitis.
BD is a chronic systemic autoinflammatory disease, characterized by recurrent uveitis, skin
lesions, oral and genital mucous ulcers, as well as some complications in central nervous
system, gastrointestinal tract and thrombotic events [2]. A high prevalence of BD has been
reported along the ancient Silk Road [3], from Asia to the Mediterranean basin countries, such
as Turkey, Iraq, Iran, Korea and Japan. The clinical features of BD have been well documented
in publications originating from the high incidence countries. Our research group has evalu‐
ated the clinical characteristics and associated ocular complications in a large group of
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consecutive Chinese BD patients and found that most patients presented a bilateral nongra‐
nulomatous anterior, posterior, or panuveitis with a chronic and relapsing course. Uveitis
occurred mostly in male patients and in the age group from the second to fifth decade of life.
Oral aphthae (100%), skin lesions (78%), and genital ulcers (57.9%) were the typical extraocular
findings in patients with BD [4].
VKH syndrome is a well-established immune-mediated multi-organ disorder characterized
by a bilateral granulomatous panuveitis frequently associated with extraocular findings
including poliosis, vitiligo, alopecia, and central nervous system and auditory signs [5]. It is
an autoimmune disease against melanocyte-associated antigens in genetically susceptible
individuals. VKH mainly affects certain pigmented races, such as Asians and Native Ameri‐
cans [5-6]. Four clinical stages of uveitis could be developed in patients with VKH syndrome:
prodromal, acute, convalescent, and chronic recurrent stages. A clinical analysis based on a
large group (n=410) of uveitis patients with VKH syndrome performed by our group showed
that the disease was diagnosed most often in young people without a gender predisposition.
The intraocular manifestations typically began with choroiditis or chorioretinitis, serous
retinal detachment, and optic disc edema, and then proceeded to anterior uveitis if appropriate
treatment was not given during the first 2 weeks. Eventually, the eyes developed a recurrent
generalized granulomatous uveitis. With regard to the extraocular manifestations, meningi‐
smus signs, tinnitus, and abnormal touch sensitivity of the hair frequently occurred before or
concurrently with ocular involvement, whereas vitiligo and poliosis usually appear after the
uveitis attack [7]. This is possibly due to the autoimmune attack against melanocytes at
different sites of the body.
Although the etiology and pathogenesis of BD and VKH syndrome is not completely known,
it is hypothesized that abnormalities in the regulation of the immune system and an immu‐
nogenetic predisposition are involved in the development of these diseases. Deregulation of
Th1, Th17 and regulatory T cells and abnormalities in the associated molecules were found to
be involved in the development of these diseases. Recently, two large genome-wide association
studies (GWAS) from Japan and Turkey reported an association between single nucleotide
polymorphism (SNP) of IL-10, IL-23R/IL-12RB2 gene and BD [8-9]. HLA-DR4 and HLA-
DRw53 were reported to be highly associated with VKH syndrome [10], implicating that
genetic factors contributed to the pathogenesis of BD and VKH syndrome. The aim of this
chapter is to expound the pathogenesis of BD and VKH syndrome with emphasis on new
insights in the area of immunoregulation and immunogenetics.
2. Th1 cells and cytokines in Behcet’s disease and VKH syndrome
Th1 cells were the first subtype of T help cells that was reported to be involved in the patho‐
genesis of autoimmune diseases. IFN-γ is the hallmark cytokine of Th1 cells. A number of
studies have determined the role of the Th1 cell and its specific cytokine repertoire in the
pathogenesis of BD and VKH syndrome. The increased levels of IFN-γ and T-bet, which is
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considered as the critical transcriptional factor for Th1 cells, have been observed in the
peripheral blood of the patients with active uveitis of BD and VKH syndrome [11-14]. Our
study found that S-Ag specific T cells may be involved in the pathogenesis of BD via the
production of Th1-dominant cytokines, but not Th17 cytokines [15]. The increased levels of
Th1 cell specific cytokines and chemokines in the cerebrospinal fluid (CSF) of VKH patients
and in the lesions of active BD patients were also reported [16-17]. El-Asrar et al found an
increased levels of IFN-γ in the aqueous humor samples of uveitis from BD, VKH syndrome
and HLA-B27-associated uveitis as compared with normal controls; and importantly, the levels
of IFN-γ were higher in BD patients than in VKH and HLA-B27-associated uveitis [18], which
suggests that IFN-γ may play more important role in the pathogenesis of BD.
In the murine uveitis models, previous reports suggested that Th1 played a pathogenic role
during experimental autoimmune uveitis (EAU) development. It was shown that mice
neutralized with monoclonal antibodies to IL-12, which drives Th1 differentiation, did not
develop EAU [19]. In order to detect whether constitutive ocular expression of IFN-γ influences
the course of EAU, Egwuagu et al generated transgenic rats with targeted expression of IFN-
γ in the eye and found that IFN-γ markedly accelerated the onset and exacerbated the severity
of rat EAU [20]. However, it has been reported that IFN-γ can also provide a protective role
in this model. Genetic deletion or neutralization with antibodies against endogenous IFN-γ
did not lead to a resistance of EAU induction and development, but rather aggravated the
severity of uveitis [21-22]. Mice treated with IL-12 during the first week after immunization
appeared to protect the animals from EAU through an IFN-γ-dependent mechanism. It has
now been demonstrated that the role of IFN-γ in the development of uveitis is dependent on
the stage of disease and the model of EAU that is being studied. IFN-γ confers protection when
it is produced during the early stage of the disease. Th1 cells play an essential pathogenic role
in the induction of the so called dendritic cell (DC) EAU model, which is induced by the
infusion of uveitogenic interphotoreceptor retinoid-binding protein (IRBP) peptide-pulsed
DCs. On the other hand, Th17 cells are essential to the induction of classical EAU, which is
induced by the immunization with IRBP in the presence of strong adjuvants such as complete
Freund's adjuvant and B. pertusis [23].
3. Th17 cells and cytokines in Behcet’s disease and VKH syndrome
Th17 cells, characterized by their production of IL-17, have been reported be associated with
the pathogenesis of many autoimmune diseases, including multiple sclerosis, rheumatoid
arthritis and systemic lupus erythematosus (SLE). Th17 cells preferentially produce IL-17A,
IL-17F, IL-21, and IL-22 [24]. IL-17A, also commonly called IL-17, plays a critical role in the
development of allergy and autoimmune responses. IL-17F is mainly involved in mucosal host
defense mechanisms, while not required for the induction of experimental autoimmune
encephalomyelitis (EAE) and Collagen-induced arthritis (CIA) [25]. As yet no reports have
appeared on the role of IL-17F in the pathogenesis of uveitis, thus, whether IL-17F is involved
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in human uveitis and EAU needs further investigation. This section aims to review studies
regarding Th17 cells and related cytokines in the development of BD and VKH syndrome.
Various studies have shown that Th17 cells contribute to the pathogenesis of BD and VKH
syndrome. The previous reports from ours and others have shown that the level of IL-17 by
polyclonally stimulated peripheral blood mononuclear cells (PBMCs) and CD4+T cells, and the
frequency of IL-17–producing CD4+T cells in PBMCs was higher in patients with active BD or
VKH syndrome than the controls [11-12, 26]. Geri et al reported an increase of Th17 cells in
peripheral blood and in CSF from active BD patients [27]. Animal studies showed that IL-17
may play a major role in the pathogenesis of EAU. The neutralization of IL-17 by monoclonal
antibodies prevented or reversed the intraocular inflammation in the EAU model [28-30].
Adoptive transfer of Th17 cells could induce EAU in the absence of INF-γ [29]. These results
indicate that IL-17 plays a proinflammatory and pathogenic role in autoimmune uveitis, and
the blockade of IL-17 signaling may represent a therapeutic target in BD and VKH syndrome
as well as in other Th17 cell-mediated autoimmune diseases.
IL-21, a member of the IL-2 family of cytokines, can drive Th17 differentiation in an autocrine
manner [31-32]. We recently reported a higher level of serum IL-21 and IL-21 mRNA in PBMCs
from patients having chronic or recurrent active VKH syndrome as compared with patients
having inactive VKH syndrome or healthy controls. Moreover, in vitro experiments showed
that IL-21 significantly increased IL-17 production, but had no influence on IFN-γ production
by PBMCs or CD4+T cells obtained from either patients or healthy controls [33]. Geri et al
observed higher levels of serum IL-21 and IL-21-producing CD4+T cells in BD patients. IL-21
was found to be able to drive Th1 and Th17 differentiation and suppressed the frequency of
Treg cells. More importantly, they demonstrated the presence of IL-21-producing T cells in the
CSF, choroid plexus, brain parenchyma inflammatory infiltrates and intracerebral blood
vessels in active BD with CNS involvement [27]. These results suggest that IL-21 may be
involved in the pathogenesis of BD and VKH syndrome and may represent a novel therapeutic
target for these diseases. The pathogenic role of IL-21 in autoimmune uveitis is supported by
animal models. IL-21R-deficient mice are resistant to EAU, and adoptive transfer of IL-21R-/-T
cells reduced the EAU severity. Increased IL-21 in lymph nodes and spleens has been reported
during the development of EAU [34-35]. All these findings provide evidence for a role of IL-21
in the pathogenesis of uveitis by promoting Th1 and Th17 cell responses and inhibiting Treg
cell development.
IL-22, a member of the IL-10 cytokine family, has recently been reported to be involved in a
number of human diseases, including mucosal-associated infections and inflammatory
disorders of the intestine, skin and joints. In view of the biological function, controversial
effects of IL-22 have been observed in different animal models and human disease. IL-22 seems
to play a pathogenic role in experimental arthritis and dermatitis, whereas a protective effect
was found in inflammatory bowel disease, experimental hepatitis and collagen-induced
arthritis [36-37]. Sugita et al showed that the frequency of IL-22-producing T cell clones from
aqueous humor of Behcet’s uveitis was higher than that from normal controls. Furthermore,
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they demonstrated that CD4+T cells from PBMCs secrete increased amounts of IL-22 in BD
patients with active uveitis. Higher IL-22 levels in the supernatants of stimulated PBMCs and
CD4+T cells and an increased frequency of IL-22-producing CD4+T cells in BD patients with
active uveitis were also reported by our group. In addition, increased IL-22 mRNA expression
was found in erythema nodosum (EN) skin lesions, and positively correlated with the presence
of EN [38]. The group of Nussenblatt reported an upregulated expression of IL-22 in PBMCs
of clinical uveitis patients. IL-22 was shown to damage the physiological integrity of primary
fetal retinal epithelium cells and induced their apoptosis [39]. These results suggest that an
increased IL-22 may also be involved in the pathogenesis of BD. However, studies in a mouse
model of uveitis showed that IL-22 can protect mice from the development of uveitis by
inducing the generation of regulatory CD11b+antigen-presenting cells, which were able to
convert pathogenic T cells into regulatory T cells [40]. As mentioned, the role of IL-22 in human
clinical uveitis and animal models remains controversial and needs further investigation.
4. Molecules modulating Th1 or Th17 cells in Behcet’s disease and VKH
syndrome
The induction and maintenance of Th1 and Th17 cells requires a large set of molecules. The
differentiation of Th17 cells from naïve CD4+T cells is regulated by cytokines [41]. Transform‐
ing growth factor-β (TGF-β) and IL-6, broadly expressed by many cell types in the body,
including dendritic and epithelial cells, are dominant in the initiation of Th17 cell differentia‐
tion [42-45]; IL-23, IL-1β and IL-21, which are products of activated DCs, macrophages,
activated T cell or inflamed epithelial cells, possibly expand and maintain the differentiated
Th17 cells in the presence of IL-6 and TGF-β1 [31-32, 43, 46-47]. Furthermore, signal transducer
and activator of transcription 3 (STAT3) has been found to mediate the initiation of Th17 cell
differentiation by these inducing cytokines [48]. IL-12 is an important cytokine responsible for
Th1 cell differentiation. IL-27 can induce Tr1 cell differentiation while inhibiting Th17 cell
differentiation.
IL-6 has been shown to be a critical mediator of the autoimmune response and inflammation.
Various studies have demonstrated that IL-6 was associated with disease activity in BD [49-50].
Studies by Norose et al showed that the level of IL-6 was significantly increased and correlated
with the number of lymphocytes in aqueous humor from VKH patients [51]. The infiltrated T
cells in the aqueous humor or PBMCs obtained from VKH patients showed an enhanced
capability to secrete IL-6 as compared to normal controls [51-52]. Ozdamar et al found that
serum levels of IL-6 were higher in BD patients with active uveitis than in those without uveitis
[53]. A higher level of IL-6 was also reported in the CSF of patients with active BD with nervous
system involvement [54-55]. A case report by Hirano et al showed that tocilizumab, a human‐
ized anti-interleukin 6 receptor antibody, could suppress the clinical manifestations in a patient
with refractory BD [56]. Consistent with observations in clinical uveitis, IL-6-deficient mice
were not able to generate Th17 cells and were resistant to EAU. Systemic administration of
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anti-IL-6 receptor antibody ameliorated EAU by suppressing both systemic and regional Th17
responses [57-58]. Taken together, these findings suggest that IL-6 is involved in the patho‐
genesis of BD and VKH syndrome, and IL-6 blockade may provide a therapeutic efficacy in
treating ocular inflammation in patients with BD or VKH syndrome.
IL-23, which is composed of a unique p19 subunit and a shared p40 subunit of IL-12, is essential
in the survival and maintenance of pathogenic Th17 cells. Our earlier studies provided
evidence for the involvement of IL-23 in the occurrence of uveitis in BD and VKH syndrome.
Active uveitis in both diseases showed a higher level of IL-23 in the serum and supernatants
of PBMCs as compared to inactive patients and normal controls [11-12]. IL-23p19 mRNA
expression was increased in the EN-like skin lesions from BD patients [59]. Studies by
Habibagahi et al showed that the IL-23 expression was strongly associated with the disease
activity of uveitis with BD [60]. These results suggest that IL-23 may be a biomarker in the
course of BD and VKH syndrome. Animal studies have shown that IL-23 is necessary for the
induction of EAU due to its capacity to promote a Th17 effector response. It has been shown
that IL-23KO mice are resistant to EAU and specific anti-IL-23 antibody prevented EAU
induction [29]. These findings support the hypothesis that the IL-23/IL-17 pathway is involved
in the pathogenesis of intraocular inflammation in BD and VKH syndrome.
IL-1β is a key proinflammatory cytokine that promotes Th17 cell differentiation. We recently
observed a higher IL-1β production by peptidoglycan (PGN)/lipopolysaccharide (LPS)–
induced monocyte-derived macrophages from active ocular BD patients [61]. Pay et al showed
a significantly increased level of IL-1β in synovial fluid from BD patients as compared to that
from osteoarthritis patients [62]. These results suggest that IL-1β may play a critical role in the
pathogenesis of BD. The pathogenic role of IL-1β in uveitis was also proven directly by the
observation that IL-1 receptor deficient mice were completely resistant to EAU [63].
IL-12, a heterodimeric cytokine composed of the subunits p40 andp35, is known to induce the
differentiation of naïve CD4+T cells into Th1 cells. Studies on the role of IL-12 in clinical uveitis
have shown that IL-12 levels in plasma and PBMC culture supernatants were higher in BD
with active uveitis [64-65]. Actual measurements of IL-12 in VKH syndrome have not yet been
reported. Many studies have shown that Th1 cells are involved in VKH syndrome [13-14],
which makes it likely that IL-12 is involved in the pathogenesis.
IL-27, a member of the IL-12 family of cytokines, has been shown to be able to inhibit Th17
cells and that it can induce regulatory Tr1 cells. IL-27 is composed of a unique p28 subunit and
a shared EBI3 subunit with IL-35. Our studies on VKH found a decreased IL-27P28 mRNA
expression by PBMCs and the lower IL-27 levels in the serum and supernatants of PBMCs in
active VKH patients as compared to the inactive patients and normal controls, while the shared
EBI3 mRNA expression was not different between the three groups. Furthermore, IL-27 was
shown to inhibit the Th17 cell response in a direct manner on CD4+T cells as well as by
modulating DCs. Treatment with corticosteroids has been shown to upregulate IL-27 produc‐
tion in vivo and in vitro [66]. An increased levels of IL-27 have been reported in the serum of
uveitis patients with BD [67]. Various animal models have been used to examine the role of
IL-27 in autoimmune disease and found that the presence of IL-27 could protect mice from
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EAE and CIA [68-69]. In the EAU model, an increased expression of IL-27 was observed at the
peak of EAU, and further experiments showed that IL-27 could suppress the expansion of Th17
cells in the retina [70]. These observations suggest that an upregulated IL-27 response may
contribute to the self-limited inflammation seen in the EAU model. Further clinical studies are
needed in clinical uveitis and EAU to obtain further support whether IL-27 may be a potential
therapeutic target for BD and VKH syndrome.
Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine that plays a significant
role in the pathogenesis of many inflammatory and autoimmune diseases. It has been reported
that the level of TNF-α was increased in the ocular fluids, serum and in the supernatants of
stimulated CD4+T cells from active uveitis patients with BD. Furthermore, TNF-α could induce
the polarization of Th17 cells in BD patients [71-72]. A similar result was seen in the aqueous
humor of VKH patients concerning the expression of TNF-α [18]. In the animal models of EAU
it was shown that TNFR1-deficient mice were resistant to EAU through a TNFR1-dependent
deficit in macrophage migration to the inflammatory site [73]. Treatment with systemic or local
TNF-α inhibition with etanercept in the induction phase of EAU could effectively alleviate the
severity of uveitis [74]. The pathogenic role of TNF-α in uveitis was also supported by
experiments that showed that TNF-α could disrupt morphologic and functional barrier
properties of polarized retinal pigment epithelium cells [75]. Thus, these results also indicate
that TNF-α plays an important role in the pathogenesis of uveitis and has provided the basis
as a major target for treating inflammatory and autoimmune eye diseases. In clinical trials, a
number of reports have shown encouraging results in treating BD and VKH syndrome with
anti-TNF-α antibody, such as infliximab [76-77].
A number of other immune-related molecules were also found to be associated with the
pathogenesis of BD or VKH syndrome. Our most recent studies have revealed that other
proinflammatory mediators, such as osteopontin (OPN), IL-7 and leptin, were also involved
in the pathogenesis of BD and/or VKH syndrome. We observed the increased serum levels of
OPN, IL-7 and leptin in patients with active BD and/or VKH syndrome, which may promote
both Th1 and/or Th17 polarization [78-81]. Consistent with our findings, it has been shown
that OPN aggravated the severity of EAU, and blockade of OPN with siRNA prevented the
uveitis development [82-83]. IL-7 and leptin have been reported to be involved in the induction
and progress of EAE, a model that shares many immunopathogenic mechanisms with EAU
[84-85].
Other regulatory molecules may also play a critical role in controlling autoimmunity. 1,25-
Dihydroxyvitamin D, miRNA155, IFN-α and IFN-β have all been shown to have an anti-
inflammatory role in autoimmune disease. Levels of 1,25-Dihydroxyvitamin D3 and
miRNA155 have been shown to be decreased in BD and VKH syndrome. Furthermore, 1,25-
Dihydroxyvitamin D3 and miRNA155 were shown to inhibit Th17 cell responses [86-87],
supporting its protective role in both BD and VKH syndrome. IFN-α has been effective in
treating uveitis in patients with BD and our studies on the possible mechanisms showed that
it could inhibit the Th17 cell response and was able to induce the expression of the regulatory
cytokine IL-10 [88]. Studies in the animal model of uveitis showed that IFN-β exerted its
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inhibitory effect on EAU by inhibiting the Th1 and Th17 cell response [89], suggesting a
protective role in uveitis.
5. Treg cells in Behcet’s disease and VKH syndrome
Treg cells maintain the immune balance between effector and tolerogenic immune responses.
It is well documented that a deficiency in Treg cells can result in the development of autoim‐
mune disease and adoptive transfer of Treg cells effectively prevented and suppressed the
severity of inflammation and/or autoimmune disease. Up to now, several subsets of Treg cells
have been identified, such as the TGF-β-secreting Th3 regulatory cells [90], CD8+CD28-T cells
[91] and NKT regulatory cells [92]. However, the best characterized subsets of CD4+regulatory
T cells are CD4+CD25+FoxP3+Tregs and Tr1 cells that secrete IL-10 and lack FoxP3 expression.
The important protective role played by these T-regulatory cells in the control of inflammatory
and autoimmune disease has generated considerable interest in patients with noninfectious
uveitis including BD and VKH syndrome.
CD4+CD25+FoxP3+Tregs can be divided into two subpopulations: natural Treg cells (nTreg),
which are develop as a distinct lineage of cells in the thymus, and the induced Treg cells (iTreg),
which are generated in the periphery from naïve CD4+T cells. They can also be induced in vitro.
The difference and relative contributions in immune response of nTreg and iTreg cells are
difficult to distinguish. A recent study found that a cell surface molecule neuropilin-1 was
expressed on thymus-derived nTreg cells, but not on mucosa-generated Foxp3+iTreg cells
[93-94]. This marker can now be used to distinguish the subsets of CD4+CD25+Tregs. Our
studies showed a decreased frequency of CD4+CD25+Treg cells and CD4+CD25+Foxp3+Treg
cells in the peripheral blood from active VKH patients. CD4+CD25+Treg cells from active VKH
patients showed a diminished function in suppressing the proliferation of CD4+CD25-T cells
and were less potent in inhibiting the production of IFN-γ and IL-13 by CD4+CD25-Tcells [95].
These results suggest that a decreased frequency and diminished function of CD4+CD25+Treg
cells are associated with the active uveitis seen in VKH patients. However, Commodaro et al
found no significant differences in the frequency of CD4+Foxp3+and CD25+Foxp3+T cells as well
as no reduction in FOXP3 mRNA expression in mononuclear cells from VKH patients with
active or inactive uveitis as compared with healthy controls [96]. The discrepancy may be due
to the difference in Tregs subtypes investigated in the two studies (iTreg or nTreg). Patients
with BD showed a significantly decreased frequency of Treg cells [27, 97], suggesting that the
low level of Treg cells may contribute to the pathogenesis of ocular attacks in BD patients.
Tr1 cells are defined by their high expression of IL-10 and their ability to suppress antigen-
specific effector T cell. Unlike CD4+CD25+Treg cells, which are present from birth, Tr1 cells are
inducible cells and can be generated both in vitro and in vivo. It has been reported that IL-27
or CD46 activation in the presence of IL-2 can induce the differentiation of Tr1 cells [98-99]. A
defect of CD46-mediated Tr1 cells has been reported in multiple sclerosis [98]. A study by our
group revealed a decreased IL-10 production by naïve CD4+T cells under Tr1 cell polarizing
conditions in active VKH patients as compared with inactive VKH patients and healthy
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controls [66], suggesting that a defect of Tr1 cells might contribute to the pathogenesis of VKH
syndrome.
Animal studies showed that Treg cells are involved in the remission of ocular inflammation.
nTreg cells and iTreg cells induced by LPS-activated bone marrow dendritic cells inhibited the
development of EAU. An increased frequency of CD4+CD25+Treg cells was associated with
the EAU activity, and these Treg cells from EAU mice have a stronger ability to inhibit the
proliferation of CD4+CD25-T cells and decreased IFN-γ production by CD4+CD25-T cells
compared with those obtained from normal control mice. Moreover, transfer of
CD4+CD25+Treg cells obtained from EAU mice on day 14 or 28 inhibited EAU induction [100].
These results suggest that the increased frequency and inhibitory effect of CD4+CD25+Treg
cells in EAU mice may contribute to the monophasic nature and rapid resolution of EAU. Shao
and his colleagues found that the suppressive function of Treg cells from animals with
recurrent EAU was weaker than those from animals with the monophasic form, indicating that
the dysregulation and malfunction of Treg cells in the eye contributed to disease recurrence
[101]. Taken together, these results offer an explanation why the uveitis in the BD and VKH
syndrome is recurrent while the uveitis in the EAU model is monophasic. The observations
demonstrate the important role of Foxp3+Treg cells in maintaining immune tolerance and
preventing autoimmunity. Thus, it could be hypothesized that Treg cells in vitro expansion
and adoptive transfer back to the patient might be a potential treatment for BD and VKH
syndrome.
6. Genetic factors in Behcet’s disease and VKH syndrome
The majority of BD is sporadic, but its familial aggregation has been reported [102-103]. BD
can be found all over the world, however, its prevalence is particularly high in a peculiar region
along the Silk Road extending from the Mediterranean basin to China [2, 104]. BD has been
shown to be strongly associated with HLA-B51, which has been confirmed in different ethnic
groups [105-106]. Previous studies showed that VKH syndrome is more prevalent in particular
ethnic groups, particularly in pigmented groups [7] including Latin-American and Asian
populations and displays a familial aggregation pattern [107]. Several HLA genes such as
HLA-DR4 and HLA-DRw53, were strongly associated with VKH in a variety of ethnic groups
[10, 108-109]. The aforementioned evidence as provided a strong genetic basis for BD and VKH
confirmed by familial aggregation, geographical ethnic distribution, and strong association
with especially Human leukocyte antigen (HLA) antigens. The genes associated with Behcet’s
disease and VKH syndrome are summarized in Tables 1 and 2, respectively.
6.1. Risk genes in Th1 cell pathway associated with Behcet’s disease and VKH syndrome
STAT4, a transcription factor belonging to the Signal Transducer and Activator of Transcrip‐
tion protein family, is required for Th1 development of naive CD4+T cells. Our study has
identified an associated locus at STAT4 for BD in a Chinese Han population, and indicated
that the risk SNP rs897200 in the STAT4 gene played a pathogenic role through an effect on
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STAT4 transcription and IL-17 production [110]. The association of STAT4 with BD was
confirmed in a Turkish population [111], suggesting that STAT4 is a common risk gene for BD
in different ethnic cohorts.
C-C chemokine receptor type 1 (CCR1) and CCR3 play important roles in the accumulation
and activation of inflammatory cells such as the Th1 cell. Recent studies showed that a locus
at CCR1/CCR3 was associated with BD in Chinese Han and Turkish populations [111-112].
Functional studies showed a higher expression of CCR1 and migration of monocytes was
found in individuals with the risk genotype [111], suggesting that impaired clearance of
pathogens may contribute to the development of BD.
IL-18 is a proinflammatory cytokine that stimulates the production of IFN-γ in collaboration
with IL-12 by Th1 cells. Studies from Turkish and Korean populations have shown the
consistent association with BD in spite of inconsistent result in Korean cohorts [113].
TNF-α has been implicated in the pathogenesis of BD and anti-TNF-α represents an important
treatment modality for BD patients [114]. A meta analysis showed an association of TNF-α
gene polymorphisms with BD in various ethnic populations [115-117].
6.2. Risk genes in the Th17 cell pathway associated with Behcet’s disease and VKH
syndrome
Accumulative evidence supports the important role of the IL-23/Th17/IL-17 pathway in
mediating chronic inflammatory or immune diseases such as BD and VKH syndrome [11, 95]
and suggests the involvement of genes related to this pathway such as IL23R-IL12RB2, JAK1,
STAT3, IL-1β, IL-6, IL17 and OPN in BD and VKH syndrome. We investigated the association
of IL23R genes with BD in the Chinese Han population [118]. The results showed that two
SNPs in IL23R were associated with the susceptibility to BD. Genome-wide association studies
also confirmed the association of IL23R-IL12RB2 with BD in Japanese, Turkish and Iranian
patients [8-9, 119]. Additionally, we identified the association of STAT3, JAK1, MCP-1 genes
with BD in a Chinese Han population [120-122]. Other genes in the Th17 pathway such as IL-6
and IL-1β also showed an association with BD [123-124].
OPN, also known as bone sialoprotein I or early T-lymphocyte activation, may enhance T cell
survival and proliferation, and promotes the responses of Th1 and Th17 cells during chronic
inflammatory or immune mediated diseases. We examined the OPN serum level in VKH
syndrome and the association of OPN polymorphisms and its receptors with this disease [80].
The results showed that the OPN level was significantly increased in the serum of active VKH
patients and identified an association of this gene with VKH syndrome in a Chinese Han
population. Furthermore, we found the association of JAK1, IL17F with VKH syndrome
[125-126]. These studies suggest that genetic variants of cytokines associated to the Th17
pathway may play an important role in the development of BD and VKH syndrome.
6.3. Risk genes in the Treg cell pathway associated with Behcet’s disease and VKH syndrome
Mir-146a, one of the miRNAs prevalently expressed in Treg cells, is known as a negative
regulator of innate immunity in a variety of immune diseases [127]. We examined the associ‐
Ophthalmology - Current Clinical and Research Updates452
ation of polymorphisms in mir-146a with BD and VKH syndrome in a Chinese Han population
and found that a polymorphism in this gene was associated with BD but not with VKH
syndrome [128].
7. Innate immunity in Behcet’s disease and VKH syndrome
It has been reported that infection may be involved in the pathogenesis of BD and VKH
syndrome. Most of the uveitis patients with BD or VKH syndrome have manifestations of a
bacterial or viral infection before the prodromal stage [129-130], suggesting that infectious
agents may be a triggering factor to the onset of these diseases. DCs serve as professional
antigen-presenting cells and provide the first line of defense against pathologic infections. Toll-
like receptors (TLRs) expressed on DCs play a critical role in innate immunity against these
pathologic infections. Interaction of DCs with TLR ligands results in the secretion of a number
of proinflammatory cytokines that can induce the differentiation of naïve CD4+T cells into
different CD4+T cells, including Th1, Th17 and Treg cells. Kirino and his colleagues reported
that an increased expression of TLR4 is associated with heme oxygenase-1 reduction in PBMCs
from patients with BD, leading to augmented inflammatory responses [131]. The study by Do
et al showed a higher level of TLR2 and TLR4 in monocytes from active BD patients [132]. Our
recent study showed a higher expression of TLR2, TLR3, TLR4 and TLR8 by either PBMCs,
CD4+T cells or monocytes obtained from BD patients as compared with controls. Furthermore,
significantly higher levels of IL-1β were produced by monocytes from active BD patients
stimulated with known TLR ligands such as LPS and PGN [133]. These results suggest that a
higher expression of TLR is associated with ocular Behcet’s disease and may partly explain the
mechanism by which infection was involved in the pathogenesis. It has been reported that DC
deregulation was implicated in the pathogenesis of BD [134]. DCs play a critical role in
determining the immune balance between self and non-self and this area is becoming a hotspot
for researchers to develop tolerogenic DCs for treating autoimmune disease [135].
8. Summary
With the recent progress in immunology and genetics, environmental triggering factors such
as viruses, bacteria or other molecular mimicry are thought to be participated in the outbreak
of BD and VKH through interacting with TLRs. The imbalance of pathogenic Th1/Th17 and
regulatory T cells and abnormalities in the associated immunoregulatory molecules with the
abovementioned T cells are now supposed to be involved in the pathogenesis of these two
diseases. The understanding of novel pathogenic mechanisms of both diseases may provide a
foundation for developing new strategies to better treat the uveitis.
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Genes Odd Ratio 95% Confidence Interval Ethnic References
CCR1/CCR3 0.28 0.2–0.4 Chinese [112]
CCR5 2.37 1.1- 5.1 Italian [136]
CD40 1.98 1.38-2.83 Chinese [137]
CPVL 2.26 1.47–3.45 Turkish [138]
eNOS 1.88 1.27-2.49 Turkish [139]
3.2 1.4-7.3 Korean [140]
1.26 2.13-3.62 Tunisian [141]
ERAP1 4.56 2.88-7.22 Turkish [111]
FCRL3 0.7 0.5–0.9 Chinese [142]
ICAM1 1.26 2.13-3.62 Tunisian [143]
4.2 1.9-9.3 Italian [144]
IL1β 3.63 1.23–12.97 Turkish [123]
IL4 3.40 1.72–7.12 Turkish [145]
IL6 3.5 1.2-10.0 Korean [124]
IL10 1.20 1.02-1.40 Iran [119]
1.45 1.34-1.58 Turkish, Arab, Greek, UK,
Korean, Japanese
[9]
1.45 1.32–1.60 Japanese, Turkish,
Korean
[8]
IL12B 1.8 1.0–3.3 Japanese [146]
IL18 1.48 1.10–1.97 Turkish [147]
IL23R-IL12RB2 1.51 1.27–1.78 Iran [119]
1.28 1.18-1.39 Turkish [9]
1.35 0.95–1.91 Japanese,Turkish, Korean[8]
1.86 1.39 -2.49 Chinese [118]
IRF-1 3.71 1.778-7.770 Korean [148]
KIAA1529 2.04 1.45–2.88 Turkish [138]
LOC100129342 1.84 1.32–2.58 Turkish [138]
m.709G >A 1.40 1.0-1.97 Iranian [149]
MCP1 1.51 1.05–2.17 Chinese [122]
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Genes Odd Ratio 95% Confidence Interval Ethnic References
MDR1 3.03 1.41-6.54 Turkish [150]
MIF 1.46 1.19–1.79 Chinese [151]
miR-146a 1.33 1.17-1.52 Chinese [128]
MMP2 0.6 0.44-0.87 Korean [152]
MMP9 0.371 0.152-0.905 Korean [153]
MTHFR 1.70 1.23–2.35 Turkish [154]
NRAMP1 1.88 1.21-2.93 Turkish [155]
PDGFRL 0.59 0.49–0.72 Chinese [156]
Protein Z 6.8 2.6-17.9 Turkish [157]
PTPN22 2.4 1.2 to 4.7 UK, Middle East [158]
SLC11A1 0.60 0.37-0.95 Korean [159]
STAT3 1.712 1.238–2.369 Chinese [121]
STAT4 1.45 1.3-1.6 Chinese [110, 160]
1.27 1.17–1.37 Turkish [111]
SUMO4 23.40 2.33-235.54 Korean [161]
1.41 1.01-1.97 Tunisian [162]
1.7 1.3–2.2 Chinese [106]
TGFBR3 0.617 0.441-0.863 Chinese [163]
TLR4 1.96 1.26-3.26 Korean [164]
1.67 1.08-2.60 Japanese [165]
TNF-α 1.68 1.10-2.56 Moroccan [116]
3.08 1.73-5.47 Iranian Azeri Turk [117]
TNFAIP3 2.03 1.65-2.49 Chinese [166]
TREM-1 2.723 1.285-5.770 Korean [167]
UBAC2 1.5 1.2-1.7 Chinese [168]
UBASH3B 1.71 1.23–2.38 Turkish [138]
VDR 1.89 1.32-2.71 Tunisians [169]
VEGF 0.10 0.011-0.875 Korean [170]
Table 1. Summary of the associated genes with Behcet’s disease
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